Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2983735rdf:typepubmed:Citationlld:pubmed
pubmed-article:2983735lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0524637lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0027908lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0011685lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0013870lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C1707391lld:lifeskim
pubmed-article:2983735lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:2983735pubmed:issue5lld:pubmed
pubmed-article:2983735pubmed:dateCreated1985-4-15lld:pubmed
pubmed-article:2983735pubmed:abstractTextRats were treated with electroconvulsive shock (ECS), desmethylimipramine (DMI), ECS plus DMI, or diazepam. In vitro analyses showed that chronic ECS produced an elevated density of recognition sites for [3H]imipramine (IMI) in platelet membranes, but had no effect on membrane preparations derived from cortical tissue. A similar elevation in receptor binding was seen exclusively in platelets after chronic ECS plus DMI, whereas no effect was observed with DMI alone. Equilibrium dissociation constant (KD) values for [3H]IMI were also increased in platelet membranes from rats given chronic ECS or ECS plus DMI treatment. Chronic ECS or DMI administration produced a decreased density of beta-adrenergic recognition sites in frontal cortex and cerebellum as assessed by [3H]dihydroalprenolol (DHA) binding. The combination of ECS plus DMI produced a similar decrease. In addition, chronic diazepam administration produced a down-regulation of the beta-adrenergic receptor only in the cerebellum. These data provide evidence for the differential regulation of brain and peripheral neurotransmitter recognition sites.lld:pubmed
pubmed-article:2983735pubmed:languageenglld:pubmed
pubmed-article:2983735pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:citationSubsetIMlld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2983735pubmed:statusMEDLINElld:pubmed
pubmed-article:2983735pubmed:monthMarlld:pubmed
pubmed-article:2983735pubmed:issn0006-2952lld:pubmed
pubmed-article:2983735pubmed:authorpubmed-author:MeyersonL RLRlld:pubmed
pubmed-article:2983735pubmed:authorpubmed-author:WennogleL PLPlld:pubmed
pubmed-article:2983735pubmed:authorpubmed-author:BOYDJ FJFlld:pubmed
pubmed-article:2983735pubmed:authorpubmed-author:ClodyD EDElld:pubmed
pubmed-article:2983735pubmed:issnTypePrintlld:pubmed
pubmed-article:2983735pubmed:day1lld:pubmed
pubmed-article:2983735pubmed:volume34lld:pubmed
pubmed-article:2983735pubmed:ownerNLMlld:pubmed
pubmed-article:2983735pubmed:authorsCompleteYlld:pubmed
pubmed-article:2983735pubmed:pagination679-83lld:pubmed
pubmed-article:2983735pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:meshHeadingpubmed-meshheading:2983735-...lld:pubmed
pubmed-article:2983735pubmed:year1985lld:pubmed
pubmed-article:2983735pubmed:articleTitleEffect of chronic desmethylimipramine or electroconvulsive shock on selected brain and platelet neurotransmitter recognition sites.lld:pubmed
pubmed-article:2983735pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2983735pubmed:publicationTypeIn Vitrolld:pubmed